News

Net profit of Biocon rose 349.36% to Rs 141.10 crore in the quarter ended June 2026 as against Rs 31.40 crore during the previous quarter ended June 2025. Sales rose 9.76% to Rs 4291.80 crore in the quarter ended June 2026 as against Rs 3910.10 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales4291.803910.10 10 OPM %19.7419.59 - PBDT688.50569.10 21 PBT141.10114.10 24 NP141.1031.40 349 Powered by Capital Market - Live News

Biocon announced the commercial launch of Yesafili� (aflibercept-jbvf) in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA� (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation* by the U.S. Food and Drug Administration in May 2024, allowing substitution at the pharmacy level in accordance with state laws. Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, �The launch of Yesafili�️ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea�️ 2 mg, advancing access to life-changing medicines for patients around the world.�

Biocon will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Biocon has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee� (insulin glargine) at its insulin manufacturing facility in Malaysia. Supplies to Europe from this line are expected to begin from Q2FY27.

Biocon announced that its long-standing partner, Duopharma Biotech Berhad (Duopharma Biotech) via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year. As part of these contracts, Biocon`s subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia. The contracts comprise a three-year agreement valued at ~ MYR 155.27 million for human insulin, along with two 2-year agreements: ~ MYR 18 million for insulin glargine and ~ MYR 52.5 million for insulin aspart. In line with policies indicated in the 13th Malaysia Plan (RMK-13) and the New Industrial Master Plan 2030 (NIMP 2030), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply.